| DIRECT COMPETITOR COMPARISON | |
| OMPI | AGN | LRLCY.PK | PHMD | Industry | | Market Cap: | 240.81M | 17.82B | N/A | 11.42M | 102.37M | | Employees: | 218 | 8,300 | N/A | 171 | 65 | | Qtrly Rev Growth (yoy): | -4.30% | 3.90% | N/A | -2.30% | 19.70% | | Revenue (ttm): | 98.83M | 4.34B | N/A | 32.66M | 14.01M | | Gross Margin (ttm): | 79.61% | 83.19% | N/A | 47.55% | 65.68% | | EBITDA (ttm): | 17.73M | 1.13B | N/A | -8.02M | -12.30M | | Oper Margins (ttm): | 15.45% | 22.19% | N/A | -38.34% | -137.11% | | Net Income (ttm): | 8.71M | 561.90M | N/A | -13.55M | N/A | | EPS (ttm): | 0.394 | 1.842 | N/A | -1.507 | -0.32 | | P/E (ttm): | 27.89 | 31.82 | N/A | N/A | 16.19 | | PEG (5 yr expected): | 1.38 | 1.64 | N/A | N/A | 1.32 | | P/S (ttm): | 2.45 | 4.13 | N/A | 0.33 | 9.50 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.50 | 0.74% | 58.20B | 12.54 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.74 | -0.21% | 13.81B | 15.98 | | Genzyme Corp. | GENZ | 51.29 | 0.35% | 13.61B | 29.24 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.54 | 0.30% | 41.88B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.04 | 0.55% | 9.10B | 1041.63 | | Teva Pharmaceutical Industries Limited | TEVA | 53.94 | 1.05% | 47.52B | 49.35 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.68 | 0.35% | 4.00B | 19.42 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.77 | -1.01% | 2.92B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.51 | 1.54% | 5.66B | 113.56 | | Pfizer Inc. | PFE | 18.74 | -0.58% | 151.22B | 15.56 | | Johnson & Johnson | JNJ | 63.88 | 0.58% | 176.25B | 13.95 | | GlaxoSmithKline plc | GSK | 42.38 | -0.07% | 107.43B | 13.50 | | Sanofi-Aventis | SNY | 39.75 | 1.09% | 103.79B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.77 | -0.69% | 126.66B | 16.70 | | RHHBY.PK | 41.43 | 0.07% | N/A | N/A | | AstraZeneca plc | AZN | 45.93 | 0.42% | 66.60B | 9.22 | | Abbott Laboratories | ABT | 54.44 | -0.07% | 84.20B | 14.75 | | Bristol-Myers Squibb Co. | BMY | 24.77 | 0.49% | 49.07B | 12.81 |
|
| NEWS ON DIRECT COMPETITORS | |
| | AGN | | AEGON Announces Offering of USD 500 Million of 4.625% Senior Notes Tue, Nov 24 -
PR Newswire | | | AGN | | [video] Healthcare Stocks: Safe and Speculative Mon, Nov 23 -
at TheStreet.com | | | AGN | | [$$] Banks Flexing Their M&A Muscles Mon, Nov 23 -
at RealMoney by TheStreet.com | | | AGN | | UPDATE - Spectrum inks deal with Korea's Handok for cancer drug Mon, Nov 23 -
at Reuters | | | AGN | | Winners, losers in U.S. Senate health bill Sat, Nov 21 -
at Reuters | | | PHMD | | PHOTOMEDEX INC Financials Sat, Nov 21 -
EDGAR Online Financials | | | PHMD | | PHOTOMEDEX INC Files SEC form 10-Q, Quarterly Report Mon, Nov 16 -
EDGAR Online | | | PHMD | | Cashing In on Obamacare Fri, Nov 13 -
at Motley Fool | | | LRLCY.PK | | L'Oreal Continues to Face Depressed Markets Sun, Nov 8 -
at Seeking Alpha | | | PHMD | | PHOTOMEDEX INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Sta Thu, Nov 5 -
EDGAR Online | | | PHMD | | PhotoMedex Appoints Christina L. Allgeier Chief Financial Officer Thu, Nov 5 -
Business Wire | | | LRLCY.PK | | L'Oreal Looking Good Fri, Aug 28 -
at Forbes.com | | | LRLCY.PK | | Ongoing Struggle At L'Oreal Wed, Aug 19 -
at Forbes.com | | | LRLCY.PK | | [video] China Watch: Avon Products Looks Pretty Fri, May 15 -
at TheStreet.com | | | LRLCY.PK | | [video] China Watch: Avon Looks Pretty Fri, May 15 -
at TheStreet.com | | | LRLCY.PK | | Mature Markets Scar L'Oreal Thu, May 7 -
at Forbes.com | | | All Headlines for these symbols... |
|
|
|